Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
Shuai Shi,Hong-Yan Ma,Yin-zhou Sang,Ying-Bo Ju,Xiao-Yun Liu,Zhi-Gang Zhang
DOI: https://doi.org/10.1155/2022/8118909
2022-07-08
BioMed Research International
Abstract:The CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) plays an extremely important role of the programed death receptor ligand-1 (PD-L1) protein. Our study is aimed at investigating the expression of CMTM6 and PD-L1 proteins in triple-negative breast cancer and their correlation with the clinical pathological data of patients. We selected 89 cases of triple-negative breast cancer and 62 cases of normal breast tissue specimens. Immunohistochemical methods were used to detect the expression levels of CMTM6 and PD-L1 and to carefully study differences in their expression. The expression of CMTM6 and PD-L1 in TNBC was higher than that in normal breast tissue, and the expression of the two was positively correlated ( p < 0.05 ). In TNBC, CMTM6 expression is positively correlated with tumor size, lymph node metastasis, Ki67 proliferation index, and TNM stage ( p < 0.05 ). PD-L1 expression is positively correlated with tumor size, lymph node metastasis, Ki67 proliferation index, TNM stage, and vascular infiltration ( p < 0.05 ). Kaplan-Meier analysis showed that the positive expression of CMTM6 and PD-L1 had no correlation with the survival rate of patients ( p > 0.05 ). According to KM-plotter, we found that a higher CMTM6 expression was positively related with relapse-free survival rate of patients ( p < 0.05 ). A higher PD-L1 expression was positively correlated with relapse-free, overall, and distant metastasis survival rate of patients ( p < 0.05 ). In timer database, we found a positive correlation between the expression of CMTM6 and PD-L1 in triple-negative breast cancer. Both CMTM6 and PD-L1 are highly expressed in TNBC, and their expressions are positively related. In the future, the two gene might become targets for the treatment of TNBC, providing a basis of clinical treatment of TNBC.
biotechnology & applied microbiology,medicine, research & experimental